Workday, Inc. R&D increased by 3.6% to $690.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 2.4%, from $674.00M to $690.00M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 9.3% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $441.62M | $444.25M | $455.62M | $537.52M | $541.51M | $547.84M | $565.73M | $591.93M | $600.00M | $610.00M | $619.00M | $635.00M | $656.00M | $649.00M | $647.00M | $674.00M | $663.00M | $660.00M | $666.00M | $690.00M |
| QoQ Change | — | +0.6% | +2.6% | +18.0% | +0.7% | +1.2% | +3.3% | +4.6% | +1.4% | +1.7% | +1.5% | +2.6% | +3.3% | -1.1% | -0.3% | +4.2% | -1.6% | -0.5% | +0.9% | +3.6% |
| YoY Change | — | — | — | — | +22.6% | +23.3% | +24.2% | +10.1% | +10.8% | +11.3% | +9.4% | +7.3% | +9.3% | +6.4% | +4.5% | +6.1% | +1.1% | +1.7% | +2.9% | +2.4% |